Scholarlink

Background <p>Adjuvant gemcitabine (aGC) is still a therapeutic mainstay after resection of pancreatic ductal adenocarcinoma (PDAC), but its efficacy is impaired by gram-negative intratumoral bacteria, suggesting a potential therapeutic implication of additive antibiotics. PDAC however, contains several other bacterial strains capable of gemcitabine degradation.</p> Methods <p>Using immunohistochemistry and fluorescence-in-situ-hybridization on the samples of a large cohort of resected PDAC patients, we examined how the intratumoral bacterial abundance affected patient outcomes with respect to aGC therapy and whether the use of pre- or postoperative antibiotics (ABT) improved the prognosis. We confirmed the findings in several independent external cohorts.</p> Results <p>High intratumoral bacterial abundance impaired aGC efficacy (disease free survival (DFS) 9.4 vs 19.1 months, <i>p</i> &lt; 0.001; overall survival (OS) 19.4 vs 34.0 months, <i>p</i> &lt; 0.001), which was mitigated by postoperative ABT application (DFS 7.9 vs 12.4 months, <i>p</i> &lt; 0.001, OS 15.2 vs 29.6 months, <i>p</i> &lt; 0.001). Postoperative ABT improved outcome of patients with low bacterial abundance in their tumors (DFS 15.1 vs 34.8 months, <i>p</i> &lt; 0.001, OS 28.5 vs 56.00 months, <i>p</i> &lt; 0.001).</p> Conclusions <p>High intratumoral bacterial abundance may predict poor response to adjuvant gemcitabine treatment, whereas postoperative ABT improves it. We propose postoperative ABT as potential additive treatment before or during aGC therapy after PDAC resection.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intratumoral bacterial abundance confers poor response to adjuvant gemcitabine in resected pancreatic cancer patients which is mitigated by postoperative antibiotics

  • 期刊论文

  • 发表日期：

    2025年6月10日

查看全文
  • Michael Guenther,
  • Sai Agash Surendran,
  • Nina Hauer,
  • Florian Fahrenschon,
  • Muhammed Dervis Arslan,
  • Steffen Ormanns

摘要

Background

Adjuvant gemcitabine (aGC) is still a therapeutic mainstay after resection of pancreatic ductal adenocarcinoma (PDAC), but its efficacy is impaired by gram-negative intratumoral bacteria, suggesting a potential therapeutic implication of additive antibiotics. PDAC however, contains several other bacterial strains capable of gemcitabine degradation.

Methods

Using immunohistochemistry and fluorescence-in-situ-hybridization on the samples of a large cohort of resected PDAC patients, we examined how the intratumoral bacterial abundance affected patient outcomes with respect to aGC therapy and whether the use of pre- or postoperative antibiotics (ABT) improved the prognosis. We confirmed the findings in several independent external cohorts.

Results

High intratumoral bacterial abundance impaired aGC efficacy (disease free survival (DFS) 9.4 vs 19.1 months, p < 0.001; overall survival (OS) 19.4 vs 34.0 months, p < 0.001), which was mitigated by postoperative ABT application (DFS 7.9 vs 12.4 months, p < 0.001, OS 15.2 vs 29.6 months, p < 0.001). Postoperative ABT improved outcome of patients with low bacterial abundance in their tumors (DFS 15.1 vs 34.8 months, p < 0.001, OS 28.5 vs 56.00 months, p < 0.001).

Conclusions

High intratumoral bacterial abundance may predict poor response to adjuvant gemcitabine treatment, whereas postoperative ABT improves it. We propose postoperative ABT as potential additive treatment before or during aGC therapy after PDAC resection.